
$190.00
per 30 mg vial
Retatrutide (Reta) is the "triple agonist": it targets GLP-1, GIP and glucagon receptors at once, one step beyond semaglutide and tirzepatide research. Key researched benefits: • Up to 24% average weight loss in a 48-week trial, among the largest results seen in this research class • Liver fat dropped by up to 86% in trial participants, with most reaching normal levels • Studied for less hunger, feeling full for longer and burning more stored fat for energy • Better blood sugar and insulin response seen in metabolic studies • Lower cholesterol, triglycerides and blood pressure reported in trial data • Growing research into heart health, brain health (including dementia risk) and healthy ageing Why researchers choose Reta: glucagon activity adds an energy-burning effect that GLP-1-only compounds do not have. 99%+ purity, independently lab tested, with batch COA reports on this page. For laboratory research use only. Not for human consumption. Published trial results do not guarantee individual outcomes.
This product will be available soon.
For research use only. Backed by manufacturer Certificates of Analysis, with independent third-party COAs published on-site where available.
Plain, unbranded packaging. No product names or logos on the outside.
Each vial is individually cushioned to protect the powder from impact.
Tracking number sent as soon as your package ships.
Confirmed lost in transit? We reship at no extra cost.
Questions about testing, shipping or returns? Read our FAQ · New batch reports: Lab updates & Telegram